2016
DOI: 10.1038/nrclinonc.2016.162
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing ‘… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

4
660
0
5

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 809 publications
(669 citation statements)
references
References 144 publications
(205 reference statements)
4
660
0
5
Order By: Relevance
“…Certain methods may not be sufficiently validated; that is, may have not crossed the two 'translational gaps' (transitioning from discovery to use in clinical hypothesis-testing and then to clinical decision-making) necessary for robust and confident use 9 . The cost of multiple imaging methods is also likely to be higher, especially in the early phases of implementation.…”
Section: Multiplexing For the Classification Of Cancer Phenotypesmentioning
confidence: 99%
“…Certain methods may not be sufficiently validated; that is, may have not crossed the two 'translational gaps' (transitioning from discovery to use in clinical hypothesis-testing and then to clinical decision-making) necessary for robust and confident use 9 . The cost of multiple imaging methods is also likely to be higher, especially in the early phases of implementation.…”
Section: Multiplexing For the Classification Of Cancer Phenotypesmentioning
confidence: 99%
“…3 [11,41]. This model for quantification of tumor vascularization was applied in multicentric studies validating the AUC as predictive marker [42,43]. …”
Section: Enhancement (Degree and Timing)mentioning
confidence: 99%
“…Oncol. 14, 169-186; 2017) 1 , James O'Connor and co-authors argue for the independent existence of 'imaging biomarkers' . They reject definitions of biomarkers that restrict "the scope of biomarkers to describing biological molecules" (REF.…”
mentioning
confidence: 99%
“…They reject definitions of biomarkers that restrict "the scope of biomarkers to describing biological molecules" (REF. 1) The investigators begin their argument by setting up a 'straw-man' definition of biomarker -one that limits the term biomarker to biological molecules. Once the straw-man is knocked down as too restrictive, they expand the definition of biomarker to include molecular, histological, and physiological characteristics -all of which are biological descriptors.…”
mentioning
confidence: 99%